Alberts Impact Ventures

Alberts Impact Ventures is the venture arm of the Alberts group in Amsterdam, investing in seed and Series A companies aligned with four impact themes, of which mental and behavioral health is one. The firm sits in the European impact-investing tradition, where measurable social outcomes are part of the underwriting standard rather than a marketing layer.

The stated thesis centers on European founders building solutions that serve underserved populations or address systemic problems, with mental health a specific named focus. For digital health and behavioral health founders, that translates to interest in evidence-based therapy delivery, population mental health platforms, employer behavioral health, youth mental health, and clinically validated consumer mental wellness with credible outcomes data. Portfolio companies are not provided in the source record; founders should request a current sheet during initial conversations to triangulate the firm’s actual mental-health depth versus its other impact themes. Check size is not disclosed in the input record.

The firm invests at seed and Series A, with geographic scope across the Netherlands and broader Europe. This makes it a credible early lead or co-lead for European behavioral health founders, particularly those with a defensible clinical evidence story and a payer or employer go-to-market pathway. Founders building in the United States should look for a US-domiciled impact or behavioral health specialist instead; cross-Atlantic seed investments are uncommon for funds of this size and structure.

Named partners are not provided in the source record, so founders should review the Alberts website and LinkedIn presence before outreach to identify the partner covering mental and behavioral health.

Approach Alberts Impact Ventures when you are a European behavioral health founder with credible clinical or outcomes evidence, a path to a regulated payer or employer customer, and a comfort with formal impact reporting in your investor relationship. They are not the right call for pure consumer wellness without outcomes data, or for US-only commercial plays. The right entry is a warm intro from a Dutch or European founder in the impact ecosystem, or via a clinical-research collaborator who knows the partnership. When pitching, be specific about which population you serve, which clinical or measurement framework you use, and how the impact metrics align with the fund’s reporting expectations, because that alignment is part of what closes the round here, not just commercial traction.